Prevail Therapeutics Inc. Arbitration Victory

“Brain”. Pixabay

Upstream provided analysis on financial damages and on trade secret protection practices for arbitration proceedings brought on by Alector Inc. against the founder and Chief Executive Officer, Asa Abeliovich, M.D., Ph.D., of Prevail Therapeutics Inc..

Prevail is a biotechnology company that develops gene therapies for neurodegenerative diseases. The company focuses on AAV-based gene therapies that have disease-modifying potential.

Prevail Therapeutics Inc. announced a victory in the July 2020 arbitration proceedings. All of the Alector’s principal claims against Dr. Abeliovich were rejected by the arbitrator. Alector had claimed that Dr. Albeliovich used trade secrets or confidential information with his work on behalf of Prevail,.

 Prevail continues to dive deep into novel therapies. In the words of Dr. Abeliovich, “our team continues to advance our pipeline and remains committed to our critical mission of developing novel, urgently needed therapies for patients with neurodegenerative disorders such as Parkinson’s disease and frontotemporal dementia.”

 In addition to submitting an expert report, Mark Chandler testified on his financial damages analysis and on trade secret protection best practices for the arbitration proceedings.